Amgen seasonal bullish setup analysis
Sidekick AI chat created on TrendSpider.
Since 2010, Amgen enters next week with a historic 81% win-rate and a 1.4% average gain. The seasonal setup emerges after a sharp recent sell-off, triggered by a failed Novartis heart disease trial which Amgen has a similar and competing pipeline for. Despite the technical panic, Amgen recently crushed Q2 earnings, raised full-year guidance, and reported stellar Phase 3 results for its separate anti-inflammatory TEZSPIRE and is in Phase 3 for its GLP-1 treatment MariTide.
Expand on this commentary to produce a full executive report. Dig into recent transcripts, Segments & KPIs, etc.
AMGN price on Sep 4, 2026 was $437.23. Today, Sep 11, 2026, it is $379.49. Price change = (379.49 - 437.23) / 437.23 = -13.2%
Executive Report: Amgen Inc. (AMGN)
Overview & Current Setup AMGN presents a notable divergence between its recent stock price action and its underlying fundamental performance. As you noted, AMGN enters next week with a strong historical seasonal tailwind (an 81% win-rate and 1.4% average gain since 2010). However, the stock has experienced a sharp recent sell-off, dropping from $437.23 on September 4 to $379.49 today. This 13.2% decline followed news on September 8 that Novartis's pelacarsen Phase 3 trial missed its primary endpoint. Financial media and analysts immediately connected this to Amgen’s competing Lp(a) pipeline drug, olpasiran, resulting in sympathy selling and several analyst downgrades (e.g., BMO Capital to Market Perform, HSBC to Hold).
Despite this technical breakdown, Amgen's Q2 2026 earnings transcript and reported KPIs reveal a robust business operating at peak revenue levels, with management raising full-year guidance.
1. The Novartis Catalyst & Amgen's Lp(a) Defense
The market's reaction centers on olpasiran, Amgen's Phase 3 candidate for modifying cardiovascular risk associated with elevated Lp(a).
During the Q2 2026 earnings call, Amgen management preemptively addressed the differences between their drug and Novartis's pelacarsen:
- Efficacy: Amgen noted that olpasiran demonstrated a ~95% reduction in Lp(a) during Phase 2, compared to the ~70% reduction seen with pelacarsen.
- Trial Design Differences: Amgen’s Phase 3 OCEAN(a) trial requires a higher baseline Lp(a) elevation (>200 nmol/L), biasing the study toward a higher-risk patient group where the drug's impact may be more pronounced. Furthermore, Amgen specifically excluded ischemic stroke from its primary 3-point MACE endpoint based on genetic data, a distinct difference from competitor trial designs.
2. Q2 2026 Financial & Segment Performance
AMGN reported over $10 billion in total Q2 revenue (a 10% year-over-year increase) and raised its full-year 2026 revenue guidance to a range of $38.2B to $39.4B. The growth was heavily supported by six key drivers which now represent nearly 70% of product sales.
Key Product Revenue Breakdown
| segment | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 9.5B | 8.2B | 9.4B | 9.1B | 8.8B | 7.9B | 8.7B | 8.2B | 8.0B |
| Repatha Revenue | 953.0M | 876.0M | 870.0M | 794.0M | 696.0M | 656.0M | 606.0M | 567.0M | 532.0M |
| Prolia Revenue | 759.0M | 727.0M | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.0B | 1.2B |
| EVENITY Revenue | 714.0M | 562.0M | 599.0M | 541.0M | 518.0M | 442.0M | 431.0M | 399.0M | 391.0M |
| TEZSPIRE Revenue | 486.0M | 343.0M | 474.0M | 377.0M | 342.0M | 285.0M | 296.0M | 269.0M | 234.0M |
- Repatha: The flagship cardiovascular drug grew 37% year-over-year, driven by a 50% increase in new-to-brand prescriptions. Recent clinical data also showed it cut death risk by 20% in high-risk heart patients.
- TEZSPIRE: Grew 42% year-over-year. As you highlighted, it recently met both co-primary and all key secondary endpoints in the Phase 3 CROSSING trial for Eosinophilic Esophagitis (EoE), expanding its addressable market beyond severe asthma.
(Chart utilizes your requested color palette to highlight the steady revenue expansion of AMGN's core growth drivers.)
3. The MariTide (GLP-1) Opportunity
While the market is heavily focused on the Lp(a) pipeline, Amgen's obesity candidate, MariTide, is progressing aggressively.
- Differentiation: According to the Q2 transcript, MariTide is a unique monoclonal antibody backbone with appended GLP-1 peptides. This structural design affords a half-life of approximately 21 days.
- Dosing Advantage: Amgen is designing MariTide to be administered monthly initially, with maintenance dosing dropping to as few as 4 to 6 times per year. This is a massive potential convenience advantage over current weekly GLP-1 injectables.
- Clinical Strategy: Amgen is running nine ongoing Phase 3 studies, not just evaluating weight loss, but exploring its impact on diabetes, heart failure, and switching patients from weekly GLP-1s to MariTide's maintenance schedule.
Summary
The current setup for AMGN juxtaposes a sharp, news-driven technical sell-off against a backdrop of peak revenue, raised guidance, and a highly differentiated pipeline. The market has priced in a heavy discount based on a competitor's failure, while Amgen's management maintains that their specific molecular design and trial parameters for olpasiran are superior. Alongside the historical seasonal strength you identified, the fundamental floor is currently being supported by massive growth in Repatha and TEZSPIRE.
Disclaimer: I am an AI, not a financial advisor. This report is based on historical data, recent news, and earnings transcripts, and should not be construed as trading or investment advice.
